National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cotellic® is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

 

Rapid Review

Commenced Completed Outcome
19/04/2016 26/04/2016 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
18/07/2016  05/01/2017 Reimbursement Not Recommended at the Submitted Price.

The NCPE does not consider cobimetinib (Cotellic®) with vemurafenib (Zelboraf®) cost-effective for the treatment of advanced (unresectable or metastatic) melanoma with the BRAF V600 mutation and therefore it is not recommended for reimbursement at the submitted price.

Summary

 

The HSE has approved reimbursement following confidential price negotiations; April 2018.